Aquestive Therapeutics (AQST) Given a $24.00 Price Target by Royal Bank of Canada Analysts

Aquestive Therapeutics (NASDAQ:AQST) has been given a $24.00 price target by research analysts at Royal Bank of Canada in a research report issued on Wednesday. The firm presently has a “buy” rating on the stock. Royal Bank of Canada’s price target points to a potential upside of 35.06% from the company’s previous close.

Other equities analysts have also recently issued research reports about the stock. Wedbush assumed coverage on shares of Aquestive Therapeutics in a research note on Wednesday, September 12th. They set an “outperform” rating and a $33.00 target price on the stock. BMO Capital Markets assumed coverage on shares of Aquestive Therapeutics in a research note on Monday, August 20th. They set an “outperform” rating on the stock. Finally, JMP Securities assumed coverage on shares of Aquestive Therapeutics in a research note on Monday, August 20th. They set an “outperform” rating and a $29.00 target price on the stock.

Shares of AQST stock traded down $0.23 during trading hours on Wednesday, reaching $17.77. The stock had a trading volume of 19,365 shares, compared to its average volume of 84,372. Aquestive Therapeutics has a twelve month low of $13.61 and a twelve month high of $20.70.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Tuesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.49) by ($0.15). The company had revenue of $13.27 million for the quarter, compared to analyst estimates of $14.75 million. As a group, research analysts forecast that Aquestive Therapeutics will post -1.02 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the business. Keybank National Association OH acquired a new position in Aquestive Therapeutics during the 3rd quarter valued at about $239,000. Engineers Gate Manager LP acquired a new position in Aquestive Therapeutics during the 3rd quarter valued at about $464,000. Wasatch Advisors Inc. acquired a new position in Aquestive Therapeutics during the 3rd quarter valued at about $2,545,000. Massachusetts Financial Services Co. MA acquired a new position in Aquestive Therapeutics during the 3rd quarter valued at about $5,305,000. Finally, Alliancebernstein L.P. acquired a new position in Aquestive Therapeutics during the 3rd quarter valued at about $14,323,000. 1.22% of the stock is currently owned by hedge funds and other institutional investors.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.

See Also: What are the benefits of a balanced fund?

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply